KaloBios
KaloBios cuts ties with former CEO Martin Shkreli, outlines ‘maniacal’ turnaround plan
August 30, 2016Research and Development, Sales and Marketing Daraprim, KaloBios, Martin Shkreli, Retrophin, benznidazole, turnaround
Two months after small drugmaker KaloBios returns from bankruptcy, controversial industry figure Martin Shkreli is no longer a stakeholder in …
KaloBios announces new affordable pricing model, refuses to engage in “price gouging”
April 12, 2016Manufacturing and Production, Sales and Marketing CEO, Drug pricing, KaloBios, Martin Shkreli, Shkreli, affordable, price gouging, price model, responsible
Price gouging has become synonymous with drug costs in the US, with the infamous Martin Shkreli and troubled Valeant becoming …
KaloBios files for bankruptcy after Shkreli arrest
January 4, 2016Sales and Marketing KaloBios, Martin Shkreli
KaloBios has filed for bankruptcy in the wake of chief executive Martin Shkreli’s arrest on securities fraud charges last month …
Sanofi Pasteur collaborates on novel biologics
January 12, 2010Research and Development KaloBios, Sanofi, Sanofi Pasteur, cystic fibrosis, infection, vaccines
Sanofi Aventis’ vaccines division has partnered with US biotech KaloBios to develop a number of novel biologic treatments. Sanofi Pasteur …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
